PEGylated nanomedicines: recent progress and remaining concerns.

Area of Science:

• Nanomedicine and Drug Delivery
• Biotechnology and Pharmaceutical Sciences

Background:

• Nanomedicine represents a significant advancement in therapeutic development, with nanocarrier drug delivery technologies gaining prominence in biopharma.
• PEGylated nanocarriers are a key component of nanomedicine, leveraging years of research into their potential for improved therapeutic performance.

Purpose of the Study:

• To discuss the drug delivery advantages of nanomedicines, with a focus on nanocarriers and PEGylated formulations currently in development.
• To highlight less commonly reported benefits of PEGylation, such as enhanced mucosal delivery, in addition to established pharmacokinetic improvements.
• To address safety considerations associated with the clinical application of PEGylated nanomedicines.

Main Methods:

• Review of general nanomedicine drug delivery benefits.
• Focused discussion on nanocarriers and PEGylated nanomedicines in clinical development.
• Exploration of established and emerging advantages of PEGylation, including mucosal delivery.
• Analysis of safety aspects of PEGylated nanomedicines in clinical settings.

Main Results:

• PEGylation offers well-established benefits like prolonged circulation for nanomedicines.
• Emerging advantages of PEGylation include enhanced physicochemical properties, biocompatibility, and significant potential for mucosal drug delivery.
• Clinical safety concerns for PEGylated nanomedicines exist but can potentially be mitigated through appropriate nanosystem design.

Conclusions:

• Nanomedicine continues to evolve, offering refined therapeutic options.
• While PEGylation is a proven tool for improving nanomedicine pharmacokinetics and offers additional benefits like enhanced mucosal delivery, these are less explored.
• Careful design of nanosystems is crucial for addressing and managing safety concerns in the clinical use of PEGylated nanomedicines.